Tianjin Medical University Cancer Institute and Hospital clinical trial pipeline

9 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 7 with minor changes only.

1. Notable

   Anrikefon Injection · Postoperative Pain in Patients Undergoing…Anrikefon Injection · Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy

   Primary and study completion pushed from Jun 30, 2026 to Dec 30, 2026

   Also in this update: Recruitment opened

   Tianjin Medical University Cancer Institute and Hospital·Phase 2· NCT07330063· Registry history of NCT07330063 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

2. Notable

   Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A…Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

   Recruitment opened

   Tianjin Medical University Cancer Institute and Hospital·Phase 2· NCT07372079· Registry history of NCT07372079 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.